Several articles focus on how to successfully diagnose Alzheimer's disease early using blood testing techniques!

January 23, 2021 // -- In three recent studies published in international journals Brain, Molecular Psython and JAMA Neurology Scientists from institutions such as the University of Gothenburg have provided compelling evidence that newly developed blood testing techniques for Alzheimer's disease may be able to diagnose diseases at an early stage and track patient progression, which is important for the development of clinical practice and therapeutic methods.
researcher Michael Sch? Because of technological developments and ground-breaking scientific advances over the past few years, Alzheimer's research is now a very active area of research, ll said, and the ideal solution would be to create a new blood testing technology for early screening for Alzheimer's disease, which could allow more people around the world to be tested and hopefully develop new therapies.
After decades of research, researchers have found that Alzheimer's-related memory problems are only the "tip of the iceberg" of the brain's underlying delincation processes, which have been potentially developing for years or even decades.
These processes are the result of amyloid and tau abnormal protein aggregations in the brain, which are decisive pathological features of Alzheimer's disease; until recently, researchers have found that it is only possible to detect these proteins in the brains of patients who have died at the time of an autopsy.
Advances in recent years have allowed scientists to use imaging techniques to detect amyloid proteins and tau pathological lesions in the brain and human cerebrospinal fluid; these so-called biomarker methods are either expensive, invasive, or can be tested at specialized centers, and currently benefit only some patients with the disease.
Photo Source: Unsplash/CC0 Public Domain An easy-to-access, affordable, minimally invasive biomarker of Alzheimer's disease has revolutionized the treatment and care of patients around the world and has been able to promote the development of new drugs that could potentially treat this incurable disease.
In 2020, researchers discovered a biomarker and developed a cheap blood test based on it to detect the presence of p-tau181, the main marker of Alzheimer's disease;
researchers conducted an unprecedentedly large study that revealed the huge potential of blood testing to predict and monitor progression of Alzheimer's disease, consisting of more than 1,100 subjects from the Alzheimer's Disease Neuroimaging Initiative, while researchers followed participants for several years.
recently developed sensitive blood testing technology for Alzheimer's disease is likely to provide a solution and could dramatically change the way the disease is managed in the near future, said Moscoso, a researcher at the University of Alzheimer's.
study published in the journal Brain, the researchers analyzed blood samples taken at different ages and constructed a time trajectory in which p-tau181 levels progressed in the blood in addition to lying in the blood during the long course of Alzheimer's disease.
importantly, the researchers found that the new blood-testing technique was able to detect abnormal levels of p-tau181 in the years leading up to a decline in participants' memory, which is important for the diagnosis of early diseases.
in a separate study published in the journal Molecular Psython, researcher Thomas Karikari further confirmed this potential by demonstrating the clinical usefulness of using p-tau181 in the blood to predict Alzheimer's disease, even in individuals who did not have any memory impairment during blood tests.
Finally, in an article published in JAMA Neurology, the researchers note that p-tau181 in the blood increases with the year or is directly related to the loss of nerve cells and cognitive decline in the body of Alzheimer's patients, revealing not only the predictive potential of p-tau181, but also an affordable way to monitor and quickly identify the disease.
researchers say the findings are important for the use of these testing techniques, both as an efficient diagnostic tool and as a measure of results in clinical trials.
researchers found that levels of p-tau181 and neurogen cellulose (NfL) in standard blood samples, or reliable biomarkers of Alzheimer's disease diagnosis, especially p-tau181, can be used as reliable markers of neurodegenerative diseases.
Overall, these studies represent a critical step in the widespread use of biomarkers in clinical practice, which can take Alzheimer's blood testing technology a step further, making it possible to use it in most clinical settings, including primary care;
() Reference: 1 Alexis Moscoso et al. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum, Brain (2020). doi：10.1093/brain/awaa399【2】Karikari,T.K.,Benedet, A.L., Ashton, N.J. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry (2020). doi：10.1038/s41380-020-00923-z 【3】Alexis Moscoso et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease JAMA Neurol. Published online January 11, 2021. DOI： 10.1001/jamaneurol.2020.4986【4】New studies support blood test for early detection of Alzheimer's diseaseby University of Gothenburg